retatrutide weight loss results clinical trials VisualAbstract: reduces body by 17.5% in patients with obesity Retatrutide shows 30% weight loss
Description
This doesnt mean you need years of failed diets, but some documented effort demonstrates that youve tried and that pharmaceutical support is warranted rather than a first-line approach
Its structure is a continuous escalation-then-maintenance arc: Initiation phase (weeks 14): 2.5 mg weekly
As with GLP-1s, coverage may also require prior authorization, a specific BMI, and consideration of other treatments first
Novo Nordisk submitted CagriSema to the FDA in December 2025, with a decision expected in late 2026 and UK availability likely in 2027 or later
All trademarks are the property of their respective owners.
Results should guide provider conversations about personalized strategies, combined with clinical assessment and biomarker data
